Sapient extends multi-omics services with high throughput discovery proteomics
Welcome to the first edition of The INsight for 2024! Enjoy the latest updates on innovations in multi-omics biomarker discovery for precision drug development.
In this issue...
- Discovery proteomics methods to extend multi-omics insights
- 5 questions to ask your discovery partner about data transparency
- Why the next population health insights lie beyond the genome
- Make your plans for Biomarkers UK 2024
These new methods enable deep coverage of the blood and tissue proteome, are scalable to thousands of samples, and allow for more measures of dynamic biomarkers in every sample. Our discovery proteomics services provide:
- Analytical specificity: with protein and PTM annotation from direct peptide measurement via mass spectrometry
- Depth & breadth: measures thousands of proteins across diverse biological pathways
- Scalable coverage and throughput: to best suit your bioanalytical needs
Importantly, these methods feed into our biocomputational pipeline for multi-omics analysis with metabolomics, lipidomics, and genomics data.
Science from Sapient: here's the latest
Biomarkers to optimize bioprocessing and scale up cell line productivity
Article: see how discovery mass spectrometry can be used to identify biomarkers to analyze, monitor, and optimize bioprocessing workflows.
Dynamic Biomarkers for Deep Immune Phenotyping in Autoimmune Disease
On-Demand Webinar: learn how these markers read out early changes in immune cell populations and drug response in the setting of autoimmune disease.
Discovery through data transparency: at the heart of scientific collaboration
Blog: We discuss key considerations regarding data transparency in scientific collaborations to ensure the accuracy and reproducibility of findings.
Advancing Population Health insights with the addition of dynamic biomarkers
Application Note: See how high throughput mass spectrometry finally gives population health studies an efficient, scalable approach to ‘go beyond the genome’ in biomarker discovery.
Meet the Sapient Team at Biomarkers UK 2024
Sapient will be attending Europe’s flagship event for biomarker research again this year, and look forward to insightful discussions on new innovations in biomarker discovery and development.
If you’ve been wanting to learn more about discovery metabolomics, lipidomics, and proteomics, we invite you to meet up with our team at Booth #21 or join our key talks. You can also schedule a time to meet by clicking here.
"Precision Medicine Beyond the Genome"
Feb 29 | 11:10am
Learn how multi-omics approaches are being integrated with genetics and applied to discover new biomarkers for drug development.
"Translating Biomarkers From Bench To Bedside"
Feb 29 | 3:50pm
Dr. Mo Jain will join experts from Eisai, AstraZeneca, and Pfizer to discuss strategies for translating biomarkers to clinical applications.
Did you know? Target metabolite & lipid panels are now available.
In addition to nontargeted discovery screenings, Sapient has developed target panels to measure specific classes of chemistries and key small molecule biomarkers of interest.
Bioanalysis Zone Feature: “Discovery technologies for the multi-omics era of precision medicine”
"Enabling the transition to the next era of precision drug development requires technologies that are both robust and scalable... that can generate accurate, precise, large-scale datasets to gain the statistical power for robust discovery."
How will the landscape of multi-omics in drug development evolve over the next 3–5 years? How are mass spectrometry-based technologies supporting this transformation? Read perspectives on these topics from Sapient's Dr. Mo Jain in this interview with the Bioanalysis Zone team.
Ready to discover more?
Sapient can help you gain the actionable knowledge needed to propel your drug development programs forward – faster and with more successful results. Let's discuss how.
10421 Wateridge Circle, Suite 100
San Diego, CA 92121
858.290.7010
Manage email preferences | Unsubscribe
©2024 Sapient Bioanalytics, LLC. All rights reserved.